Retrophin Inc (NASDAQ:RTRX) SVP William E. Rote sold 1,034 shares of the firm’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $21.50, for a total transaction of $22,231.00. Following the transaction, the senior vice president now directly owns 11,156 shares of the company’s stock, valued at $239,854. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of Retrophin Inc (RTRX) traded up $0.54 during mid-day trading on Friday, reaching $22.75. 277,279 shares of the company traded hands, compared to its average volume of 262,430. Retrophin Inc has a 12-month low of $15.55 and a 12-month high of $26.44. The company has a market cap of $876.93, a P/E ratio of -14.71 and a beta of 1.01. The company has a quick ratio of 3.83, a current ratio of 3.88 and a debt-to-equity ratio of 0.15.
Hedge funds have recently made changes to their positions in the stock. Nationwide Fund Advisors lifted its holdings in Retrophin by 14.6% during the 2nd quarter. Nationwide Fund Advisors now owns 59,424 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 7,583 shares during the last quarter. Strs Ohio bought a new position in Retrophin during the 3rd quarter valued at about $908,000. OxFORD Asset Management LLP lifted its holdings in Retrophin by 71.4% during the 3rd quarter. OxFORD Asset Management LLP now owns 59,768 shares of the biopharmaceutical company’s stock valued at $1,497,000 after purchasing an additional 24,906 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Retrophin by 49.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 825,253 shares of the biopharmaceutical company’s stock valued at $16,002,000 after purchasing an additional 271,551 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Retrophin by 8.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,635,234 shares of the biopharmaceutical company’s stock valued at $31,707,000 after purchasing an additional 125,695 shares during the last quarter.
A number of research firms have recently commented on RTRX. Zacks Investment Research raised shares of Retrophin from a “strong sell” rating to a “hold” rating in a report on Thursday, January 4th. BidaskClub raised shares of Retrophin from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. Finally, ValuEngine downgraded shares of Retrophin from a “hold” rating to a “sell” rating in a report on Saturday, February 3rd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. Retrophin presently has a consensus rating of “Hold” and a consensus target price of $44.00.
TRADEMARK VIOLATION WARNING: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://ledgergazette.com/2018/02/16/retrophin-inc-rtrx-svp-sells-22231-00-in-stock.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.